Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 25, 2005
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. Operations are conducted through two segments: Healthcare Distribution (dental, medical, and international) and Technology (practice management software and services). The company serves over 475,000 customers globally.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 25, 2005 |
Six Months Ended June 25, 2005 |
|---|---|---|
| Net Sales | $1,141,620 | $2,243,030 |
| Gross Profit | $324,412 | $630,599 |
| Gross Margin | 28.4% | 28.1% |
| Operating Income | $70,464 | $127,669 |
| Net Income | $39,974 | $73,199 |
| Diluted EPS | $0.45 | $0.82 |
| Cash from Operations (6mo) | $72,615 | |
| Total Debt (as of June 25, 2005) | $531,612 | |
| Working Capital (as of June 25, 2005) | $796,393 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 20.7% ($195.9 million) for the quarter and 22.4% ($410.7 million) for the six months compared to the prior year. Growth was driven by acquisitions (15.7% of quarterly growth) and internal volume increases.
- Segment Performance:
- International: Sales surged 71.2% in the quarter, primarily due to the Demedis Group acquisition in Europe.
- Dental: Sales grew 18.8% in the quarter, driven by consumable merchandise and equipment sales.
- Medical: Sales declined 2.9% in the quarter due to the strategic shedding of lower-margin pharmaceutical and veterinary products.
- Profitability: Gross margin improved to 28.4% (quarter) and 28.1% (six months) from 26.6% and 26.3% respectively in the prior year, aided by margin management and the mix of acquired businesses.
- Expenses: Selling, general, and administrative (SG&A) expenses increased 35.0% to $254.0 million for the quarter, rising as a percentage of sales from 19.9% to 22.2% due to payroll and integration costs from recent acquisitions.
- Interest Expense: Increased significantly due to convertible debt issued to finance the Demedis acquisition.
Guidance, Outlook, and Risks
- Acquisitions: The company completed the acquisition of Ash Temple (Canada) and the Demedis Group (Austria/Europe). Integration efforts are ongoing, with expected synergies.
- Liquidity: On May 24, 2005, the company entered a new $300 million credit facility with a $100 million expansion feature, replacing the previous $200 million facility. Management believes current cash, credit facilities, and access to capital markets are sufficient for foreseeable needs.
- Stock Repurchases: Under a $100 million program authorized in June 2004, the company had repurchased $57.3 million of stock as of June 25, 2005.
- Key Risks:
- Supply Chain: Uncertainty regarding the supply of Chiron's Fluvirin influenza vaccine for the 2005-2006 season.
- Regulatory: Exposure to changing healthcare regulations, Medicare reform, and product liability claims.
- Integration: Risks associated with integrating acquired businesses and achieving expected revenue growth.
- Interest Rates: Exposure to variable interest rates on $230 million of senior notes.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and cost of integrating the Demedis Group and Ash Temple to ensure projected synergies are realized.
- Vaccine Supply: Monitor updates on Chiron's Fluvirin production estimates and the impact on Henry Schein's seasonal revenue.
- Margin Sustainability: Assess whether the improved gross margins are sustainable given the increase in SG&A expenses related to acquisitions.
- Debt Structure: Review the terms of the new $300 million credit facility and the impact of variable interest rates on future interest expense.
- Medical Segment Strategy: Evaluate the long-term impact of shedding lower-margin pharmaceutical products on the Medical segment's revenue base.